Characterization of tumour mutation burden in patients with non-small cell lung cancer and interstitial lung disease.

Haruki KobayashiMasakuni SerizawaTateaki NaitoHayato KonnoHideaki KojimaTetsuya MizunoMitsuhiro IsakaMasahiro EndoTakeshi NagashimaMasatoshi KusuharaKenichi UrakamiKeiichi OhshimaKen YamaguchiYasuhisa OhdeToshiaki Takahashi

Published in: Respirology (Carlton, Vic.) (2019)

Squamous cell carcinoma and adenocarcinoma with ILD do not have high TMB values. Therefore, considering the risk of severe pneumonitis, immune checkpoint inhibitors should not be used routinely against patients with NSCLC and ILD based on the expectation of high TMB values.

Keyphrases

interstitial lung disease
systemic sclerosis
squamous cell carcinoma
rheumatoid arthritis
idiopathic pulmonary fibrosis
small cell lung cancer
lymph node metastasis
early onset
advanced non small cell lung cancer
radiation therapy
risk factors